• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compounds having activity in treating or preventing foot and mouth disease are disclosed. The compounds contain a sequence of the formula X-A-Y-B-Z in which A and B are amino acid residue sequences comprising sequences of the foot-and-mouth disease virus VP1 capsid protein serotypes, one of which contains from 18 to 24 amino acid residues and includes the amino acid residue sequence in positions 141 to 158 of the O serotype or the equivalent sequence of other serotypes and the other of which contains from 14 to 20 amino acid residues and includes the amino acid residue sequence in positions 200 to 213 of the O serotype or the equivalent sequence of other serotypes; X is H, H-Cys, or H-Cys-Cys, the sulfhydryls of which may be blocked or free; Z is OH, Cys-OH, or Pro-Cys-Gly-OH, the sulfhydryls of which may be blocked or free; and Y is a sequence of from about 2 to about 6 amino acid residues, or a pharmaceutically-acceptable salt thereof.
    公开号:SU1662338A3
    申请号:SU864027624
    申请日:1986-05-31
    公开日:1991-07-07
    发明作者:Дэннис Димарчи Ричард；Стивен Брук Джеральд
    申请人:Эли Лилли Энд Компани (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to biotechnology and can be used to produce antigenic determinants of VPi of the scur virus.
    Schichom's disease is highly infectious, leading to a debilitating disease that is caused by the schur virus, which is a virus of the picornavirus family of animals.
    The method of obtaining antigenic determinants of the schur virus suggests solid phase peptide synthesis (Cis-Cys (200-213) -Pro-Pro-Ser (141-158) -Pro-Cis-Gly or (200-213} -Pro-Pro-Ser (141 -158) Pro-Cis-Gly, or N-Cys Arg-Tir-Asp-Arg-Asp-Ala (141-158) -Leu-Pro-Pro-Pro-Glu-Ala (200-213) -he.
    PRI me R 1.
    I. Preparation of synthetic vaccines against ENR. All peptides are synthesized using solid phase peptide
    synthesizer using semi-automatic programming. All reagents, in all cases, unless otherwise indicated, are technically available products of the highest quality. As dichloromethane, the product (CHaCte) is used for high performance liquid chromatography. Diisopropylethylamine (DIEA) is distilled from ninhydrin before use. A copolymer resin (1% styrene and 1% divinylbenzene) is obtained in the form of beads with dimensions of 0.076-0.038 mm.
    The quality of the protected amino acids is assessed by thin-layer liquid chromatography by the angle of optical rotation by amino acid analysis and mass spectrographic analysis.
    A. Obtaining aminomethyl resin. To a thoroughly washed resin in a three-necked round-bottomed flask was added 16 g (81
    yo
    ABOUT
    about
    GO SB CJ 00

    with
    mmol) M- (hydroxymethyl) phthalimide and 2 l of a mixture of trifluoroacetic acid with methylene chloride in a volume ratio of 1: 1. With intensive stirring of the upper layer, 40 ml (0.44 mol) of trifluoromethanesulfonic acid are carefully added. After 6 hours of reaction at 22 ° C, the solution is filtered and subjected to abundant washing with a mixture of trifluoroacetic acid and methylene chloride in a 1: 1 volume ratio, methylene chloride, ethanol and finally methylene chloride again. Dry in vacuo, boil the resin under reflux for 16 hours in 2 liters of ethanol containing 5% hydrazine, filter in a warm condition and wash with 4 portions of 2 liters of boiling ethanol, 4 portions of 2 liters of methanol and 4 portions of 2 L each of methylene chloride. The product obtained is dried under vacuum. It has an amine functional activity of 0.836 mmol / g.
    8. Preparation of side glycine- 4- (hydroxymethylphenyl) acetic acid. Side-glycine-4- (hydroxymethylphenyl) acetic acid is synthesized.
    C. Attaching the resulting glycine to kaminomethyl resin. 1.4 mmol side-gly-4- (hydroxymethylphenyl) acetic acid is dissolved in 20 ml of dimethylformamide mixture
    with methylene chloride in a volume ratio of 1: 3 at 0 ° C in the presence of 1.4 mmol of 1-hydroxybenzotrizol (MBT). An equivalent amount (1.4 mmol) of dicyclohexylcarbodiimide (DCC) is then added and the reaction mixture is stirred for 10 minutes at 0 ° C, after which the dicyclohexylurea is removed by filtration and the upper layer is added to 4 g of an aminomethyl resin, suspended in 20 ml of methylene chloride. After 2 hours, the resin is filtered, washed three times with 40 ml of methylene chloride, and then suspended in 40 ml of a mixture of 0.5N. acetic anhydride with 0.1 M DIEA and methylene chloride. After another 2 hours, the resin becomes ninhydrin-negative. Next, the resin is washed three times with 40 ml of methylene chloride, after which the tert-butyloxycarbonyl protective group is removed in 40 ml of a mixture of trifluoroacetic acid and methylene chloride in a 1: 1 volume ratio.
    D. Protocol of repeating stepwise synthesis. In each case, use a double combination of each amino acid in a threefold excess of amine, Hot Asp, Gly and Apr are subjected to a double combination
    in the form of their pre-obtained OBT-esters, the remaining amino acids are first combined in the form of their previously obtained anhydrides and repeated
    in the form of their pre-obtained OBT-esters. Neutralization, removal of the protecting groups and the entire washing process are carried out fully automatically according to the following protocol in 15 ml of solvent per 1 g of the starting resin.


    (2x2 min).
    (6x1 min). (1 x 120 min.)
    (6 x 1 min). (2x2 min).
    (6x1 min). (1 x 120 min.)
    (6 x 1 min).
    (1x2 min, 1 x 20 min).
    (6 x 1 min).
    In the synthesis process, aliquots of the resin are removed to obtain truncated immunogens.
    E. Preparation of OiK, VPi (141-158) -Pro-Cis-Gly-peptide with 21 residues.
    Approximately 3 g of peptidyl resin containing 1.34 g of protected 0 | K, VPi (141-158) -Pro-CystTly, is treated with 30 ml of a mixture of hydrogen fluoride and p-cresol in a ratio of 9: 1 at 0 ° C for 60 min After completion of the cleavage reaction, the resin is evaporated to dryness in vacuo at 0 ° C, then washed with 5 portions of 50 ml of diethyl ether. The peptide released from the protecting groups is dissolved with successive treatments with acetic acid: 10% acetic acid (3 portions of 30 ml each), 50% acetic acid (1 portion of 30 ml) and 10% acetic acid (3 portions of 30 ml). Pep- The tide is freeze dried in 76% yield. Ellman titration shows that the minimum content of free sulfhydryl groups is 70%. This peptide is purified using gel permeation chromatography on Sefadex G-25 resin in 10% acetic acid, and then subjected to dithiothreitol (DTT) reduction, obtaining an exceptionally homogeneous monomer fraction, as determined by liquid chromatography high resolution.
    F. Preparation of OiK, VPi Leu-Pro-Pro-Ser (141-158) -Pro-CycTli peptide with 25 residues.
    Approximately 1.1 g of peptidyl resin, which contains 0.532 g of protected OiK, VPi Leu-Pro-Pro-Ser (141-158) Pro-Cys-Gly, is treated similarly to the above in Part E, resulting in a 84% yield target peptide.
    G. Preparation of OiK, VPi (200-213) -Pro-Pro-Ser (141-158) - a peptide with 38 residues.
    Approximately 2.4 g of peptidyl resin containing 1.29 g of protected OiK, VPi (200-213) -Pro-Pro-Ser (141-158) Pro-Cys-Gly, are treated in the same way as described in Part E, resulting in 97% yield get the target peptide.
    N. Preparation of OiK, VPi Cis-Cys (200-213) -Pro-Pro-Ser (141-158) -Pro-Cis-Gly peptide with 40 residues.
    Approximately 2.5 g of peptidyl resin, which contains 1.39 g of protected OiK, VPi Cis-Cys (200-213 Pro-Pro-Ser (141-158) -Pro-CisTli, is treated in the same way as described in Part E, with the result that peptide is obtained in 97% yield.
    Preparation of OiK, VPi H-Cys-Agr-Tir-Asp-Arg-Asp-Ala (141-158) -Leu-Pro-Pro-Tre Glu-Ala (200-213) -one-peptide with 45 residues.
    Protected OiK VPi N-Cys - Arg-Tyr-Asp-Arg-Asp-Ala- {141-158) -Leu-Pro-Pro-Tre Glu-Ala (200-213) -peptidyl resin is treated similarly to the above in Part E, whereby the peptide obtained in the preparation of this part of the example is obtained.
    PRI mme R 2. Chemical attachment of peptides to KLH through SPDP.
    The maximum appropriate level of KLH loading with M-succinimidyl-3- (2-pyridine) -propinate (SPDP) is determined according to the degree of precipitation of the complex, which is reached within 60 minutes of the reaction. A 250 molar excess of SPDP in the KLH ratio is determined to be optimal, 0.5 g of KLH (approximately 1 mmol) is dissolved in 25 ml of a 0.1 M sodium phosphate secondary solution (pH 7.2) with careful sonication. A small amount of insoluble material is removed by centrifugation, and 7.81 mg SPDP (2.5 x 10 mmol) in 625 µl of DMF is added to the upper layer. After termination of alkali absorption, the sample is centrifuged and desalted on top of Sephadex G-25 in a 0.1 M solution of secondary sodium phosphate at pH 7.2 and a speed of 20 cm / h. It is established that the level of load achieved in the process of formation of the derivative is approximately 40% by DTT recovery.
    To 100 mg of functionalized KLH (2 x 106 ligand) in 25 ml of a 0.1 M solution of secondary sodium phosphate (pH 7.2) are added
    0 tenfold excess (44 mg) (141-158) - Pro-Cys-Gly reduced peptide in 600 μl of 0.1 M trimethylolaminomethyl (pH 7.4). The progress of the reaction is monitored by the release of the ligand, which almost completes quantitatively within 60 minutes at 22 ° C. The sample is desalted with Sefacryl S-200 resin in a 0.1 M ammonium bicarbonate solution (pH 7.5) and lyophilized. The yield of peptides with 21, 25 and 38 residues in
    0, calculated on a limited reagent, is 84, 85 and 68%, respectively.
    The preparation of compositions based on peptides.
    All peptides and conjugates
    5 KLH peptide is dissolved in 10 µM trimethylaminomethane (pH 8.0) to the desired concentration, after which it is diluted in a 1: 1 ratio with Freund's complete adjuvant. Overall volume,
    0 and the concentration of antigen administered to each animal are described for each experiment.
    Ii. Biological protocol.
    A. Vaccination of guinea pigs. During
    5 conducting all experiments use female guinea pigs weighing 450-500 g. Each vaccine preparation is administered into the body at the indicated dosage by subcutaneous injection in a volume of 0.15 mp for each member.
    0 groups of guinea pigs from five animals. The only exception to the indicated total dose volume of 0.15 ml is the dose of 0.45 ml, which is used for antigenic dosage.
    5 titration to achieve the highest set concentration. The control vaccine was prepared using strain Oi Kanfbenren, the only one for which data were published
    0 sequences. The vaccine is prepared using aluminum hydroxide gel, and it contains 1.66 mg of saponin per dose. Each of the five guinea pigs is injected with 1 ml subcutaneous injection.
    5 vaccines. As a viral pathogen, as indicated above, use strain 0 | Kanfbenren. During the viral titration process, a 1/20 dilution is performed in order to obtain an infection dose of 3000 infectious doses per animal. All experimental animals are infected with a subcutaneous virus injection into the pad of the left hind paw in a volume of 0.02 ml. Each infected guinea pig is observed over the next 7 days, following the development of secondary or general lesions of the other hind leg or front legs and mouth. The criterion of protection is the absence of some lung-secondary lesions.
    B. Vaccination of cattle. For all experiments, heifers aged from 6 to 8 months, weighing approximately 150-180 kg each, of mixed dilution, which are characterized by susceptibility to foot and mouth disease, are used. Each vaccine preparation is administered into the body in the indicated dosage by subcutaneous injection in a volume of 3 ml to each member of a group of three animals. In each experiment, a group of three animals was not vaccinated (control animals). All animals were infected by subcutaneous injection of 104 Dso freshly titrated OIBFS viruses in a dose volume of 0.1 ml in ten points of the language. After infection, animals are examined daily to detect an increase in body temperature and develop a lesion on the tongue and legs. Animals are considered to be protected from the disease in the absence of any secondary lesions developing seven days after infection.
    C. Determination of serum neutralization titers (HNS). To quantify serum neutralization titers, antibody ELISA titers are defined as directed against peptide 140-160. In all the vaccines with the use of the described peptides, an extremely close relationship was reached between the results of the ELISA determinations and the serum neutralization titers,
    Iii. Biological results.
    -
    The most convincing method for determining the relative potency of a range of synthetic peptide vaccines is the method for determining their minimum protective molar dosage. The assay shows a marked improvement in serum neutralization titres and defenses for peptides with 38 and 40 residues compared with similar results, which are up to 10 times with a 21-residue peptide.
    Peptides with 38 and 40 residues are equivalent, if judged on them within the limits of experimental error, due to
    15 which minimizes the value of amino acid terminal cis-cis-residues in the latter molecules. Both of these peptides seem to provide complete protection at a dosage that is less than
    20 0.1-0.001 dosage of antigenic peptide with 21 residues.
    At a molar dosage comparable to that which provides protection by peptide with 21 residues in
    25 Freund Complete Additive Supplement, 40 residue residue peptide provides complete protection with complete, technically available alumina hydrate additive. The absolute weight of the antigen that rescues the complete protection of the guinea pigs using this last adjuvant with a single vaccination is less than 1 mg.
    权利要求:
    Claims (1)
    [1]
    35 claims
    The method of obtaining antigenic determinants of the VPi-protein FMD of the subtype 0 | K virus, including solid-phase peptide synthesis, which is characterized by the synthesis of 40 Cis-Cys (200-213) -Pro-Pro-Ser peptides (141-158) -Pro-Cis-Gly, or (200-213) -Pro-Pro-Ser (141-158) -Pro-Cis-Gly, or H-Cys Apr-Tir-Asp-Arg-Asp-Ala (141-158 ) -Ley-Pro-Pro-Tre Glu-Ala (200-213) -one.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1662338A3|1991-07-07|Method for preparation of antigenic determinants vp- protein of fmd virus, subtype o k
    Bittle et al.1982|Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence
    Anderson et al.1993|Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide
    EP0203676A2|1986-12-03|Vaccine for generating an immunogenic T cell response protective against a virus
    IE64983B1|1995-09-20|Conjugates
    CN101659695B|2012-08-29|O-type aftosa synthetic peptide vaccine
    CN103183728B|2015-06-10|Polypeptide used for preparing O type peptide vaccine of cattle foot-and-mouth disease and preparation methods and applications thereof
    EP0120906B1|1988-09-21|Polypeptides useful in vaccination against enteroviruses
    JPH08510240A|1996-10-29|Conserved motif of hepatitis C virus E2 / NS1 region
    CN103848902A|2014-06-11|Synthetic peptide vaccine and preparation method thereof
    CA1270099A|1990-06-05|Immunogenic hav peptides
    CN102998460A|2013-03-27|Enzyme linked immunosorbent assay | kit of foot-and-mouth disease virus antibody and preparation method thereof
    US4857634A|1989-08-15|Peptides useful in vaccination against enteroviruses
    WO1991003255A1|1991-03-21|Polypeptide vaccines against foot-and-mouth disease virus
    CN101565457B|2014-04-02|Synthetic peptide vaccine and preparation method thereof
    Hilbert et al.1994|The influence of branched polypeptide carriers on the immunogenicity of predicted epitopes of HSV‐1 glycoprotein D
    CN104672312A|2015-06-03|Bovine foot and mouth disease A-type polypeptide vaccine
    CN103087156B|2013-10-09|Foot and mouth disease virus | antigen polypeptide and vaccine
    CN103936841A|2014-07-23|Peptide vaccine used for animal and its preparation
    CN101579522B|2012-09-12|Novel peptide-based vaccine used for domestic animal and preparation method thereof
    CN103224548A|2013-07-31|Polypeptide for preparing cattle foot-and-mouth disease ASIAI type peptide vaccine and preparing method and use thereof
    CN106986925B|2020-08-25|O-type and A-type bivalent synthetic peptide vaccine for bovine foot and mouth disease and preparation method and application thereof
    JP2001519800A|2001-10-23|Synthetic peptides useful in biological assays for detection of infection by group O HIV-1 virus
    CN111803626A|2020-10-23|Bivalent synthetic peptide vaccine for O-type and A-type pig foot-and-mouth disease and preparation method and application thereof
    CA1287447C|1991-08-06|Peptides useful in vaccination against enteroviruses
    同族专利:
    公开号 | 公开日
    AU595531B2|1990-04-05|
    ATA141786A|1992-11-15|
    DE3686095T2|1993-03-04|
    SG94792G|1992-12-04|
    NZ216362A|1989-04-26|
    DE3686095D1|1992-08-27|
    ES8707739A1|1987-08-16|
    EP0204480B1|1992-07-22|
    ZA863911B|1988-01-27|
    HUT41050A|1987-03-30|
    JPS61282398A|1986-12-12|
    HK101692A|1992-12-24|
    AT396248B|1993-07-26|
    CN86103718A|1987-02-04|
    EP0204480A2|1986-12-10|
    EG17812A|1990-08-30|
    KR870000426A|1987-02-18|
    CN1019267B|1992-12-02|
    IL78913D0|1986-09-30|
    AU5821286A|1986-12-11|
    KR890003944B1|1989-10-13|
    PT82651A|1986-06-01|
    GR861406B|1986-09-30|
    DK251286D0|1986-05-29|
    PT82651B|1988-11-30|
    DK251286A|1986-12-04|
    US4732971A|1988-03-22|
    EP0204480A3|1989-02-08|
    ES555668A0|1987-08-16|
    IL78913A|1991-01-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4140763A|1976-09-08|1979-02-20|The United States Of America As Represented By The Secretary Of Agriculture|Vaccine for foot and mouth disease|
    AU547096B2|1980-05-12|1985-10-03|Biogen N.V.|Foot-and mouth disease viral antigens|
    EP0068693A3|1981-06-16|1983-07-20|Genentech, Inc.|Production of foot and mouth disease vaccine from microbially expressed antigens|
    ZA831854B|1982-03-26|1984-01-25|Biogen Nv|Small peptides with the specificity of foot and mouth disease viral antigens|
    DE3382459D1|1982-04-14|1991-12-19|James L Bittle|ARTIFICIAL PIKORNAVIRUSANTIGEN.|US6074650A|1985-06-24|2000-06-13|Hoechst Aktiengesellschaft|Membrane anchor/active compound conjugate, its preparation and its uses|
    US6024964A|1985-06-24|2000-02-15|Hoechst Aktiengesellschaft|Membrane anchor/active compound conjugate, its preparation and its uses|
    US5864008A|1988-03-25|1999-01-26|James; Stephen|Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides|
    ZW6189A1|1988-05-09|1990-05-09|Smithkline Beckman Corp|Anti-aggregatory peptides|
    CN1059347C|1992-03-27|2000-12-13|牧岩生命工学研究所|A novel process for preparing a vaccine for hemorrhagic fever with renal syndrome|
    CN1054544C|1993-10-21|2000-07-19|复旦大学|Polypeptide vaccine for aftosa and its preparation|
    US5538733A|1994-07-07|1996-07-23|Willmar Poultry Company, Inc.|Method of priming an immune response in a one-day old animal|
    US6096863A|1996-08-23|2000-08-01|Regents Of The University Of Minnesota|Self-assembling amphiphiles for construction of peptide secondary structures|
    DE19638044A1|1996-09-18|1998-03-19|Bayer Ag|Immunogenic peptides from foot-and-mouth disease viruses|
    US6048538A|1997-10-03|2000-04-11|United Biomedical, Inc.|Peptides derived from the non-structural proteins of foot and mouth disease virus as diagnostic reagents|
    EA003101B1|1998-03-19|2002-12-26|Бристол-Майерз Сквибб Компани|Biphasic controlled release delivery system for high solubility pharmaceuticals and method|
    US6107021A|1998-06-20|2000-08-22|United Biomedical, Inc.|Synthetic peptide vaccines for foot-and-mouth disease|
    US8058248B2|2001-04-26|2011-11-15|The United States Of America As Represented By The Secretary Of Agriculture|Foot and mouth disease virus vaccine comprising interferons|
    CN100342911C|2004-01-13|2007-10-17|厦门大学|Bivalent DNA vaccine of type A and type O foot-and-mouth disease virus and its preparing process|
    EP3861986A1|2008-09-17|2021-08-11|Chiasma, Inc.|Pharmaceutical compositions comprising polypeptides and related methods of delivery|
    ES2575860T3|2010-07-09|2016-07-01|Bhv Pharma, Inc.|Combined immediate / delayed release delivery system for short half-life pharmaceutical products that include remogliflozin|
    CN104244973B|2012-11-16|2017-10-20|美国联合生物医学公司|For the urgent vaccine based on synthetic peptide of aftosa |
    US10478487B2|2015-01-16|2019-11-19|Zoetis Services Llc|Foot-and-mouth disease vaccine|
    CN107365367A|2017-08-16|2017-11-21|山东省农业科学院奶牛研究中心|A types FMDV VP1 Protein Epitopes gene polypeptide and its application|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US74078085A| true| 1985-06-03|1985-06-03|
    [返回顶部]